About Day One
Day One Biopharmaceuticals is here to support your child’s journey
Day One Team.
Our team includes experts with backgrounds in pediatric oncology, nursing, and drug development. We are researching and developing therapies specifically for pediatric cancers like pLGG
We put kids first
The life-altering news of a pLGG diagnosis is a startling change for your family and what it may mean for your child. That’s why at Day One Biopharmaceuticals, we want to reshape that outlook by helping children lead lives full of every opportunity possible.
We put kids first. Our experience in pediatric cancer—including working with pediatric oncology doctors and nurses—helps us understand and cater to the unique needs of families. Inspired by the urgent needs of children with cancer, our goal is to develop new medicines as quickly as possible for those living with pLGG.
We are developing therapies targeted at specific tumor Alteration = a type of genomic change (mutation or fusion) in the BRAF gene that may contribute to cancer development , focusing first on BRAF = a gene that, when altered, may be a driver of pLGG growth Alteration = a type of genomic change (mutation or fusion) in the BRAF gene that may contribute to cancer development (BRAF fusion = 1 of the 2 most common types of BRAF alterations in pLGG (ie, KIAA1549-BRAF fusion) or BRAF point mutation = 1 of the 2 most common types of BRAF alterations in pLGG (ie, BRAF V600E)) in pLGG.
Learn more at https://www.dayonebio.com.
